TLR2 and non-small cell lung carcinoma: The novel TLR2/1 agonist WYJ-2 inhibits the proliferation of NSCLC by promoting the formation of TLR2/1 heterodimers, activating the NF-κB signaling pathway, and inducing the focal death mechanism (Wang et al., 2024c).